This content is in French.
Immunogenicity at the Heart of Chronic Inflammatory Treatments
4 décembre 2024
The advent of biosimilars, such as adalimumab-adbm (Cyltezo), represents
a significant advancement in the management and treatment of chronic
inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and
chronic plaque psoriasis. However, immunogenicity, which can affect the
efficacy and safety of these treatments, remains a critical concern.
This study compares the immunogenicity of adalimumab-adbm with that of its reference product (Humira) to provide valuable insights for healthcare professionals in their clinical practice.
This study compares the immunogenicity of adalimumab-adbm with that of its reference product (Humira) to provide valuable insights for healthcare professionals in their clinical practice.
Do Biosimilars Offer Comparable Immunogenicity to Their Reference Products?
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Strand, V., et al. (2024). Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials. BMJ open, 14(11), e081687.
View the source
